Olema Pharmaceuticals (OLMA) Says Falsified Information is Circulating on Social Media

November 29, 2021 4:29 PM EST

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, has been alerted to falsified information circulating on social media relating to the company’s planned poster presentation for the Phase 1 dose-escalation portion of the ongoing Phase 1/2 clinical trial of OP-1250 at the San Antonio Breast Cancer Symposium (SABCS). The falsified poster image was not released or authorized by the company.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA, Hot FDA News, Trading Halts